eagle-i The University of PennsylvaniaThe University of Pennsylvania
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Treatment Development and Delivery Program

eagle-i ID


Resource Type

  1. Program


  1. Resource Description
    Program Goals Despite the fact that cigarette smoking continues to be the greatest preventable cause of morbidity and mortality, there are currently only three FDA-approved medications for nicotine dependence: nicotine replacement therapy (NRT; transdermal nicotine (TN), nasal spray, gum, lozenge), bupropion, and varenicline. Although these treatments are effective for some smokers, nearly 75% relapse within a year. There is a clear need to identify novel treatment approaches to help more smokers quit. The Treatment Development and Delivery Program within CIRNA is guided by the following goals: (1) to develop and evaluate novel behavioral and pharmacological interventions for nicotine dependence; (2) to develop novel methods to improve the efficacy and effectiveness of FDA-approved treatment for nicotine dependence; (3) to expand the use of treatments for nicotine dependence to under-served populations.
  2. Contact
    Schnoll, Robert., PhD
  3. Affiliation
    Center for Interdisciplinary Research on Nicotine Addiction
  4. Website(s)
  5. Other members
    Lerman, Caryn., PhD
  6. Other members
    Audrain-McGovern, Janet., PhD
Provenance Metadata About This Resource Record
  1. workflow state
  2. contributor
    ggrant (Gregory Grant)
  3. created
  4. creator
    ggrant (Gregory Grant)
  5. modified
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016